1502 GMT - Novo Nordisk's early trial data of amycretin impresses on weight loss, with patients losing 22% of their body weight at the highest dose at 36 weeks, Barclays analysts write. "Novo shares are taking this well as this news finally breaks the tide of negative sentiment." Though it was a phase 1 study with a multi-part design and there is limited information on safety, the weight loss puts it on par with the best injectable data out there, Barclays says. Shares trade 11% higher at 643.80 Danish kroner.(dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 24, 2025 10:02 ET (15:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.